Pharmacoepidemiology, the study of the use and effects of pharmaceuticals in large human populations, is a bridge science spanning clinical pharmacology and epidemiology.
Pharmacovigilance is “the science and activities relating to detecting, assessing, understanding, and preventing adverse effects or any other drug-related problem.” Signal detection research, one method of Pharmacoepidemiology, enables the early detection of adverse events and pharmacological effects that were not revealed in pre-marketing clinical trials. These analytical cases have contributed significantly to the proper use of drugs. Drug discovery research takes a long time and a high cost, from compound discovery to clinical application. The probability that a new drug candidate will ultimately become a new drug and be delivered to the medical field is less than 0.01%. Therefore, drug repositioning research is expected to save time and cost in new drug development by discovering new drug effects from existing drugs that are safe in humans. The inverse signals detected by pharmacoepidemiological research have been useful in searching for candidate compounds.
In recent years, polypharmacy has become an issue, and early detection of adverse events due to drug interactions that were not identified in pre-marketing clinical trials has become one of the most important issues in clinical practice and is the latest topic in pharmacovigilance research. Meanwhile, drug repositioning research is also a current topic in synergy pharmaceutical science, which seeks to find drug combinations that offer advantages such as reducing the use of individual drugs and, in some cases, decreasing the frequency of serious adverse events. In the era of Big Data, pharmacovigilance and drug repositioning research are becoming inextricably linked. However, to obtain relevant analysis results, it is necessary to grasp and deepen our understanding of the characteristics and utilization limits of big data (databases) used in research.
This Research Topic focuses on systematic research on pharmacovigilance and drug repositioning using Pharmacoepidemiology. Reports on successful drug repositioning and time/cost comparisons between drug discovery in general and drug repositioning are also welcome. Manuscript types accepted include Original Research, Systematic Review, Methods, Reviews, Mini Review, Data Report, and Brief Research Report.
Pharmacoepidemiology, the study of the use and effects of pharmaceuticals in large human populations, is a bridge science spanning clinical pharmacology and epidemiology.
Pharmacovigilance is “the science and activities relating to detecting, assessing, understanding, and preventing adverse effects or any other drug-related problem.” Signal detection research, one method of Pharmacoepidemiology, enables the early detection of adverse events and pharmacological effects that were not revealed in pre-marketing clinical trials. These analytical cases have contributed significantly to the proper use of drugs. Drug discovery research takes a long time and a high cost, from compound discovery to clinical application. The probability that a new drug candidate will ultimately become a new drug and be delivered to the medical field is less than 0.01%. Therefore, drug repositioning research is expected to save time and cost in new drug development by discovering new drug effects from existing drugs that are safe in humans. The inverse signals detected by pharmacoepidemiological research have been useful in searching for candidate compounds.
In recent years, polypharmacy has become an issue, and early detection of adverse events due to drug interactions that were not identified in pre-marketing clinical trials has become one of the most important issues in clinical practice and is the latest topic in pharmacovigilance research. Meanwhile, drug repositioning research is also a current topic in synergy pharmaceutical science, which seeks to find drug combinations that offer advantages such as reducing the use of individual drugs and, in some cases, decreasing the frequency of serious adverse events. In the era of Big Data, pharmacovigilance and drug repositioning research are becoming inextricably linked. However, to obtain relevant analysis results, it is necessary to grasp and deepen our understanding of the characteristics and utilization limits of big data (databases) used in research.
This Research Topic focuses on systematic research on pharmacovigilance and drug repositioning using Pharmacoepidemiology. Reports on successful drug repositioning and time/cost comparisons between drug discovery in general and drug repositioning are also welcome. Manuscript types accepted include Original Research, Systematic Review, Methods, Reviews, Mini Review, Data Report, and Brief Research Report.
